logo
Could a 70 million-year-old dinosaur fossil hold the key to new cancer discoveries?

Could a 70 million-year-old dinosaur fossil hold the key to new cancer discoveries?

Independent2 days ago

Scientists believe dinosaur fossils could hold the key to new cancer discoveries and influence future treatments for humans.
A decade-long study published in the journal Biology by researchers from Anglia Ruskin University (ARU) and Imperial College London has identified preserved red blood cell-like structures in a dinosaur fossil.
The findings raised the possibility that prehistoric creatures could be used to study ancient tumours, helping to complete the 'jigsaw' of cancer's molecular building blocks, and potentially influencing future treatments for humans.
Professor Justin Stebbing, an oncologist at ARU, said the idea for the study began in 2016 after reading an article about the discovery of a new fossil in Romania with a tumour in its jaw.
The remains were those of a Telmatosaurus transsylvanicus, a duck-billed, plant-eating 'marsh lizard', a specimen that had lived between 66-70 million years ago in the Hateg Basin in present-day Romania.
'Justin said, guys, I want to go and get this tumour and see what we can get out of it,' Dr Biancastella Cereser, a cancer specialist at Imperial, said.
'We wanted to see if this tumour in the dinosaur could give us any information about any parallel with human cancers, because the tumour that this dinosaur had was an ameloblastoma, a benign tumour in the jaw, which humans have as well.'
From 2017, a team was put together, including three scientists who traditionally work on human cancers – Professor Stebbing, Dr Cereser, and Professor Pramodh Chandrasinghe from the University of Kelaniya in Sri Lanka.
'We contacted the town in Romania, which was very excited to loan us the fossil,' Dr Cereser said.
'We went to Romania and collected the specimen. We brought it back, and we basically drilled into it with a very, very, very fine drill.
'Then we mounted it into this very sophisticated microscope and imaged it. What we saw inside – there were some structures, some forms, that looked like blood cells.'
This Scanning Electron Microscopy (SEM) technique enabled the researchers to identify low-density structures resembling erythrocytes, or red blood cells, in the fossilised bone.
'Up until recently, the fossil record and finding ancient things was really interesting for finding hard things like shells or skeletons to assess tissues,' Professor Stebbing said.
'But if we're trying to look at the building blocks of life or the building blocks of cancer, to understand cancer better, what we found was you can actually as well as seeing the skeleton, we can actually see soft tissue as well.
'We could actually see like the flesh of the cancer. This means we can look at cancer not only occurring in human or in animal models, but we can look at it tens and tens of millions of years ago.
'It helps us understand the role of environment on cancer.'
He continued: ' Jurassic Park isn't right, because what they said is dinosaur DNA could be recovered and cloned to resurrect dinosaurs, but we can't get DNA out of this because it's broken down by weathering and time.
'But what we have found is that we've actually found proteins in soft tissues can survive over time.
'All we're trying to understand is the molecular building blocks of cancer from a very, very ancient perspective.
'If we can understand cancer better, we can come up with better treatments. I do a lot of research in cancer, so, you know, it all comes together. It's just part of a jigsaw that you are trying to build.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Major discovery about 'invisible' breast tumours that are too small to show up on scans
Major discovery about 'invisible' breast tumours that are too small to show up on scans

Daily Mail​

time3 hours ago

  • Daily Mail​

Major discovery about 'invisible' breast tumours that are too small to show up on scans

Thousands of women have been thrown a lifeline thanks to a 'next generation' drug that can destroy breast cancer tumours, months before they even grow. The daily pill, known as camizestrant, stops cancer cells from developing, slowing the spread of the disease and delaying the need for gruelling chemotherapy. Around seven in ten breast cancer patients in the UK have a type of the disease known as HR positive HER-2 negative breast cancer—the most common form. Of these, around 40 per cent can develop an aggressive genetic mutation that makes their outlook incredibly bleak. But the 'transformational' trial found patients given the drug camizestrant saw their risk of the cancer progressing slashed by more than half. It was also the first worldwide study that showed blood tests, rather than scans, can pick up early signs of cancer returning. Doctors first used the test, known as a liquid biopsy, to spot changes in the cancer's DNA—when they found signs of an ESR1 mutation, some patients were given camizestrant, while others stayed on their usual treatment. Experts presenting the findings today at the American Society for Clinical Oncology conference (ASCO) in Chicago, hailed it a 'pivotal moment in breast cancer care' and 'truly fundamental shift in how we approach cancer'. The drug is already being fast-tracked for use in the US and has been sent for approval in the UK. Professor Nicholas Turner, an expert in molecular oncology at The Institute of Cancer Research, London and the Royal Marsden NHS Foundation Trust, who co-led the major trial, said: 'This is a pivotal moment in breast cancer care. 'This proactive approach also redefines how we think about drug resistance in this type of breast cancer. 'This is a potential new treatment strategy in oncology to treat developing resistance before it causes disease progression.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'The results represent more than a clinical milestone—they represent a transformational shift in how we approach precision medicine. 'It is very exciting to see this technology being used to delay disease progression in patients and extend the benefits of treatment in patients with this type of advanced breast cancer and delay the need for chemotherapy for as long as possible. 'These breakthroughs are helping shape personalised breast cancer treatment, allowing doctors to adjust therapies earlier and improve patient outcomes.' In the trial, 3,325 patients HR positive HER-2 negative advanced breast cancer from 23 countries were screened for ESR1 mutations using a liquid biopsy every eight to 12 weeks. Of these, 315 women who tested positive for an ESR1 mutation were given either AstraZeneca's camizestrant and a medicine known as a CDK4/6 inhibitor or another hormone therapy as well as a CDK4/6 inhibitor. Researchers found those on the camizestrant combination slashed their risk of death or the cancer progressing by 56 per cent. The drug also kept the cancer at bay for 16 months on average compared to 9.2 months on standard treatment. Just one per cent of patients stopped taking the drug over side effects. Presenting the findings at ASCO, Susan Galbraith, executive vice president of oncology at AstraZeneca said the drug had now been given 'breakthrough therapy designation' by the Food and Drugs Administration in the US, helping to speed up regulatory review. 'We are having ongoing discussions with regulatory authorities including the UK', added. Dave Fredickson, AstraZeneca's executive vice president of oncology business unit, also said the drug demonstrated a 'truly fundamental shift in how we approach cancer care. 'We're moving away from a one size fits all era and targeting cancer early.' Meanwhile, Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment. 'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow. 'It shows how circulating tumour DNA—or ctDNA—could help doctors make smarter, more timely treatment decisions. 'This approach could become an important part of how we personalise care for people with advanced breast cancer.'

Simple lifestyle switch can slash colon cancer death by a third: 'It's better than any drug', according to top expert
Simple lifestyle switch can slash colon cancer death by a third: 'It's better than any drug', according to top expert

Daily Mail​

time3 hours ago

  • Daily Mail​

Simple lifestyle switch can slash colon cancer death by a third: 'It's better than any drug', according to top expert

An hour an a half of daily exercise could slash the risk of dying from colon cancer by more than a third, a pivotal trial has suggested. Regular exercise has long been lauded as a crucial way to not only help stave off cancer, but also lower the chances of it spreading. Now, groundbreaking research has shown patients with the disease saw their risk of death cut by 37 per cent by completing 10 hours of physical activity per week. Anything from a brisk walk to high intensity interval training (HIIT) counted, meaning patients could also choose an activity that best fitted into their lifestyle. Researchers, presenting the findings at the American Society of Clinical Oncology (ASCO) conference in Chicago today, said the study was 'one of the strongest bits of evidence that exercise works' to keep cancer at bay. ASCO president and top cancer specialist Julie Gralow added that findings suggested exercise was 'better than a drug because it doesn't involve side effects'. 'This study shows it's not too late to start exercising even once diagnosed or if patients have started treatment.' The research comes amid a rising ride of colon cancer striking people in their 20s, 30s and 40s —a phenomenon that has baffled doctors around the world. Bowel cancer can cause you to have blood in your poo, a change in bowel habit, a lump inside your bowel which can cause an obstructions. Some people also suffer with weight loss a s a result of these symptoms Over the last 30 years, young diagnoses of the disease have shot up by 80 per cent across the globe. In the world-first trial, a group of international researchers tracked 889 people from six countries, including the UK, Australia and Canada, all of who had undergone surgery and chemotherapy for colon cancer that had spread to nearby lymph nodes but not reached other organs or tissues. Half were prescribed a structured exercise programme, with the other half given health education materials alongside standard follow-up care and surveillance. Those on the exercise regime received in-person coaching sessions every week for the first six months and once a month for the following two and a half years. After five years, scientists found 80 per cent of volunteers in the exercise group remained cancer-free, compared to 74 per cent in the control contingent. They also discovered the risk of death was a third lower in the exercise group. The benefits remained after eight years—patients who stuck to the exercise programme had a 37 per cent lower risk of death, the authors reported in the New England Journal of Medicine. Professor Vicky Coyle, UK lead researcher and clinical professor at Queen's University Belfast, said: 'We supported people to reach their weekly exercise target in a way that worked for them. 'This could be a long, brisk walk every day, but some patients were also doing circuit classes, cycling, swimming, and many other activities. 'Our study gives clear, encouraging evidence that physical activity can reduce the risk of cancer returning for some people with colon cancer.' Dr Joe Henson, study co-author and associate professor in lifestyle medicine at the University of Leicester, added: 'I saw first hand that the exercise reduced fatigue, lifted people's mood, and boosted their physical strength.' He added more research is needed to uncover the reasons behind the positive impact of exercise. Previous research has suggested that exercise can trigger the release of chemicals in the blood that help the immune system hunt and destroy cancer cells. Studies have also found that regular exercise reduces levels of inflammatory proteins in the body that are known to fuel the development of tumours. Natasha Wood, now 40, who lives in London, was diagnosed with stage three colon cancer in 2015 at the age of just 30. She had surgery, followed by six months of chemotherapy and has been in remission since 2016. Ms Wood, who completed half-marathons before her diagnosis, was told by doctors that her baseline fitness level would improve her outcomes. She said: 'The results of this trial corroborate my own personal experience whereby exercise has played a pivotal role both during treatment and in the years following. 'Throughout my treatment I continued to run, swim, cycle and lift weights, habits I've retained in the decade since. 'Exercise has been a cornerstone of my own healthy lifestyle and supported my physical and mental health in equal measure.' The disease, the third most common cancer in the UK, is the same type that killed Dame Deborah James aged 40 in 2022. Although the vast majority of diagnoses affect those aged over 50, rates in older age-groups has either declined or held stable while diagnoses in younger adults have soared over the last 30 years. Doctors have suggested obesity, antibiotic over-use, mobile phone radiation and even invisible particles of plastic in drinking water are potential triggers. However, a growing number of experts are also pointing to ultra-processed foods as a cause. Around 32,000 cases of colon cancer are diagnosed every year in the UK and 142,000 in the US. Symptoms include changes in bowel movements such as consistent and new diarrhoea or constipation, needing or feeling the need to poo more or less frequently and blood in the stool. Stomach pain, a lump in the stomach, bloating, unexpected weight-loss and fatigue are among other common signs.

Major charity shop with over 600 stores across the UK to close city site after 35 years
Major charity shop with over 600 stores across the UK to close city site after 35 years

The Sun

time4 hours ago

  • The Sun

Major charity shop with over 600 stores across the UK to close city site after 35 years

A MAJOR charity chain with over 600 stores has confirmed it will shut one of its beloved high street branches in weeks. Cancer Research UK has announced it would be closing its Plymoth location this month after 35 years of serving the local community. 2 2 Cancer Research in Stoke, Plymoth is shutting up shop for the last time on June 21. The decision was made in March with bosses saying the store was "no longer a financially viable option". A charity spokesperson said: "This decision was not taken lightly, as we understand the significant impact a shop closure can have on the community. "We have a responsibility to ensure that we are using charity funds effectively and efficiently to maximise our contribution to life-saving research. "Whilst we explore all avenues before making the decision to close a shop, unfortunately, the Stoke (Plymouth) shop was no longer a financially viable option." They thanked the staff and volunteers for having been "powerful ambassadors" for the charity. Locals have been left heartbroken at the news with Councillor Jemima Laing calling the shop "part of the fabric of life" in the community. She told BBC: "People have described it [the shop] to me as a 'hub' which is so much more than a shop and offers a listening ear to people, often grieving, as they drop off their donations." The shop has put out a notice board with the bittersweet message from the staff. The sign read: "Our last day of trading will be Saturday, 21st June, which is a very sad for myself, my wonderful volunteers and of course you, our customers. "In the meantime please continue to support the shop, the only charity shop in the village!" Beloved department store chain shutting more locations with clearance sales on now until final May 25 deadline Customers can also leave goodbye messages in the book at the store before it closes for good. It comes as another charity is set to close 77 branches this year with the majority already shut. Disability charity Scope, which has locations in England and Wales, revealed they have been struggling financially. The closures were first announced in January as part of a move that could see 1 38 of the brand's stores ceasing operation. Bosses explained the chain has experienced declining footfall and increasing costs, including higher rents as well as staff costs and energy bills. RETAIL PAIN IN 2025 The British Retail Consortium has predicted that the Treasury's hike to employer NICs will cost the retail sector £2.3billion. Research by the British Chambers of Commerce shows that more than half of companies plan to raise prices by early April. A survey of more than 4,800 firms found that 55% expect prices to increase in the next three months, up from 39% in a similar poll conducted in the latter half of 2024. Three-quarters of companies cited the cost of employing people as their primary financial pressure. The Centre for Retail Research (CRR) has also warned that around 17,350 retail sites are expected to shut down this year. It comes on the back of a tough 2024 when 13,000 shops closed their doors for good, already a 28% increase on the previous year. Professor Joshua Bamfield, director of the CRR said: "The results for 2024 show that although the outcomes for store closures overall were not as poor as in either 2020 or 2022, they are still disconcerting, with worse set to come in 2025." Professor Bamfield has also warned of a bleak outlook for 2025, predicting that as many as 202,000 jobs could be lost in the sector. "By increasing both the costs of running stores and the costs on each consumer's household it is highly likely that we will see retail job losses eclipse the height of the pandemic in 2020."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store